Yeganeh Pasebani

Yeganeh Pasebani

Auto-generated profile, based on publicly available information

Yeganeh Pasebani

Rajaie Cardiovascular Medical and Research Center

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2023 in Journal of Vascular Surgery: Venous and Lymphatic Disorders
Verified
Journal Article
Closed access
MBMohammadreza Babaei
Mohammadreza Babaei
AAArya Afrooghe
Arya Afrooghe
ARAli Rafati
Ali Rafati
BMBahram Mohebbi
Bahram Mohebbi
JMJamal Moosavi
Jamal Moosavi
PSParham Sadeghipour
Parham Sadeghipour

5 February 2024 in Cardiology Research and Practice
Verified
Journal Article
Open access
PDF file
AEAmin Elahifar
Amin Elahifar
ARAli Rafati
Ali Rafati
MAMohammad Javad Alemzadeh-Ansari
Mohammad Javad Alemzadeh-Ansari
YPYeganeh Pasebani
Yeganeh Pasebani
BNBehshad Naghshtabrizi
Behshad Naghshtabrizi
SHSeyed Kianoosh Hosseini
Seyed Kianoosh Hosseini
Objective. Primary percutaneous coronary intervention (PCI) is the best treatment for acute ST-elevation myocardial infarction (STEMI). Evidence is in favor of ticagrelor over clopidegrel in STEMI patients regarding the reduction of stent thrombosis risk during and after PCI. We compared initial thrombolysis in myocardial infarction (TIMI) flow in STEMI patients on ticagrelor vs. clopidogrel. Methods. This prospective cohort recruited 160 patients with acute STEMI, referred to the emergency department of Farshchian Heart Center, during March 2018–2019. Before angiography, the patients received clopidogrel (600 mg) or ticagrelor (180 mg) on top of aspirin. Initial TIMI flow was compared between the two groups as the primary outcome. A logistic regression was performed to calculate the predictors of initial TIMI flow. Analyses were performed using R, version 4.2.1. Results. In ticagrelor and clopidogrel groups, the mean ± standard deviation age of the patients was 59.46 ± 13.11 and 61.34 ± 11.08 years (p value = 0.33), respectively. In the ticagrelor and clopidogrel groups, initial TIMI flow grades were as follows: 0 : 50% and 71.2%, I: 26.2% and 16.2%, II: 12.5% and 10%, and III: 12.9% and 2.5%, respectively (p value = 0.005). Final TIMI flow grades were as follows: I: 26.2% and 16.2%, II: 7.5% and 13.8%, and III: 66.3% and 70%, respectively (p value = 0.41). Ticagrelor was associated with significantly higher initial TIMI flow grade compared to the clopidogrel group (adjusted odds ratio: 2.90 (95% CI: 1.51–5.72)). Conclusion. In STEMI patients who were candidates for primary PCI, ticagrelor administration led to a better initial TIMI flow grade compared to clopidogrel.

26 October 2022 in medRxiv
Verified
Preprint
Open access
PDF file
ARAli Rafati
Ali Rafati
YPYeganeh Pasebani
Yeganeh Pasebani
MJMelika Jameie
Melika Jameie
YYYuchen Yang
Yuchen Yang
MJMana Jameie
Mana Jameie
Amir KheradmandAmir Kheradmand
Amir Kheradmand
Background and Objective: Bell’s palsy (BP) has been considered as a serious adverse event following the SARS-CoV-2 vaccination. Many studies have reported BP following vaccination, although neither a causative relationship nor a prevalence of the condition higher than the general population has been established. The outcomes of interest were to compare BP incidence among (a) SARS-CoV-2 vaccine recipients, (b) nonrecipients in the placebo or unvaccinated cohorts, (c) different types of SARS-CoV-2 vaccines, and (d) SARS-CoV-2 infected vs. SARS-CoV-2 vaccinated individuals. Methods: We performed a systematic search through MEDLINE (via PubMed), Web of Science, Scopus, Cochrane library, and Google Scholar from the inception to August 15, 2022. We included articles reporting individuals receiving any SARS-CoV-2 vaccine in whom BP had occurred. Studies reporting facial paralysis due to etiologies other than BP were excluded. Random- and fixed-effects meta-analyses using the Mantel-Haenszel method were conducted for the quantitative synthesis. Newcastle-Ottawa scale (NOS) was used to assess the quality. The study was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline, and the protocol was registered with PROSPERO (CRD42022313299). Analyses were carried out using the R, version 4.2.1 (R package ‘meta’ version 5.2-0). Results: Fifty studies were included, of which 17 entered the quantitative synthesis. First, pooling four phase-3 randomized controlled trials (RCT) indicated BP occurrence was significantly higher in SARS-CoV-2 vaccines (77, 525 doses) compared to placebo (66, 682 doses) (OR = 3.00, 95% CI = 1.10 - 8.18, I 2 = 0%). Second, pooling nine observational studies of mRNA SARS-CoV-2 vaccine doses (13, 518,026) and matched unvaccinated individuals (13, 510,701) revealed no significant increase in the odds of BP in the vaccinated group compared to the unvaccinated group (OR: 0.70 (95% CI 0.42-1.16), I 2 =94%). The third meta-analysis suggested that post-vaccination BP among first dose Pfizer/BioNTech recipients (22,760,698) did not significantly differ from that in first dose Oxford/AstraZeneca recipients (22,978,880) (OR = 0.97, 95% CI = 0.82 - 1.15, I 2 = 0%). According to the fourth meta-analysis, BP was significantly more commonly reported after SARS-CoV-2 infection (2,641,398) than after SARS-CoV-2 vaccinations (36,988,718) (RR = 4.03, 95% CI = 1.78 - 9.12, I 2 = 96%). Conclusion: Our meta-analysis suggests a higher incidence of BP among vaccinated vs. placebo groups. BP occurrence did not significantly differ between Pfizer/BioNTech and Oxford/AstraZeneca vaccines. SARS-CoV-2 infection posed a significantly greater risk for BP than SARS-CoV-2 vaccines.

7 December 2022
Verified
Preprint
Open access
PDF file
ARAli Rafati
Ali Rafati
FSFarshid Sharifi
Farshid Sharifi
YPYeganeh Pasebani
Yeganeh Pasebani
AKAli Kabiri
Ali Kabiri
MHMohammad Amin Habibi
Mohammad Amin Habibi
NSNiloufar Samiei
Niloufar Samiei
Background Mitral regurgitation (MR) is the most common valvular heart disease. Since delaying severe MR treatment can lead to left ventricular dysfunction, early MR diagnosis is crucial. Echocardiography is the first-line diagnostic modality for evaluating MR severity. Transesophageal echocardiography (TEE) and newer imaging modalities like cardiac magnetic resonance imaging (CMR) are growing to be used due to the pitfalls of transthoracic echocardiography (TTE). However, these newer modalities have disadvantages, such as high cost, requiring highly-skilled operators, and expensive devices, that make them not widely available in developing countries. We evaluated novel TTE-derived hemodynamic burden parameters of MR to estimate and classify MR severity more precisely. Methods We prospectively enrolled 93 patients with primary MR from April 2022 to August 2022. We obtained the baseline characteristics and the following TTE parameters: mitral valve (MV) velocity-time integral (VTI), left ventricular outlet (LVOT) diameter (D), LVOT VTI, and mitral valve annulus (MVA) diameter. The statistical analysis was performed using SPSS. Results A total of 93 MR patients with a median (interquartile range) age of 59.00 (50.50-65.00) were recruited, of whom 38 (40.9%) were female. Of the 93 patients, 29 (31.2%), 29 (31.2%), and 35 (37.6%) were classified into mild, moderate, and severe MR, respectively. The four parameters of MVVTI/LVOTVTI, MVAVTI-index (i), MVAVTI/LVOTDVTI, and E velocity-LA area-i were shown to be significantly different among mild, moderate, and severe MR groups (p-values <0.001). Spearman’s correlation test indicated that MVVTI/LVOTVTI, MVAVTI-i, MVAVTI/LVOTDVTI, and E velocity-LA area-i were highly and significantly correlated with MR severity classification with correlation coefficients of 0.776, 0.672, 0.822, and 0.698, respectively (p-values <0.001). The ROC-curve analysis demonstrated that all parameters were significantly accurate predictors of severe MR diagnosis. The area under curve (AUC) of the MVVTI/LVOTVTI, MVAVTI-i, MVAVTI/LVOTDVTI, and E velocity-LA area-i were 0.976, 0.975, 0.986, and 0.895, respectively (p-values <0.001) Conclusion We introduced novel TTE-derived MR hemodynamic burden indices. These indices were highly correlated with MR severity. Furthermore, they were significantly accurate predictors of severe MR. Proposing such new indices to older measures may improve their predictive value.

3 October 2022
Verified
Preprint
Open access
PDF file
YPYeganeh Pasebani
Yeganeh Pasebani
ZKZohre Kahe
Zohre Kahe
ARAli Rafati
Ali Rafati
NSNastaran Salimi
Nastaran Salimi
YRYousef Rezaei
Yousef Rezaei
NSNiloufar Samiei
Niloufar Samiei
Background Cardiovascular complications are frequently reported among patients with pulmonary coronavirus disease 2019 (COVID-19) infection. Echocardiography has been immensely implemented for diagnosing cardiovascular involvements. We aimed to evaluate the changes in echocardiographic parameters in health care workers infected with COVID-19 during follow-up. Methods This prospective study was conducted during Iran’s third COVID-19 wave in November 2020 among health care workers who were infected with COVID-19 but otherwise healthy. A total of 100 patients underwent echocardiographic examination six to eight weeks following recovery, an early follow-up. Six months after the COVID-19 diagnosis, as the late follow-up, 63 subjects underwent echocardiographic evaluations. Moreover, based on clinical and radiological evidence, individuals were categorized into two groups of non-severe and severe COVID-19. Results The participants’ mean age was 40.4±8.1 years. In the non-severe COVID-19 group, Right Ventricle Free-Wall Global Longitudinal Strain (RVFWGLS) significantly decreased in the follow-up echocardiogram (-32.3±4.6% vs. -28.8±5.8%, p-value=0.002). RV Fraction Area Change (RV-FAC) (46.6% [43.6-53] vs. 39.7% [25-43] , p-value <0.001) and, Tricuspid Annular Plane Systolic Excursion (TAPSE) (21 mm [19-24] vs. 23 mm [20-25], p-value=0.09) did not show a significant change. In the severe COVID-19 group in late echocardiogram, RVFWGLS showed no statistically significant change (-28.3%±3.5 vs. -28.6%±5.1, p-value=0.79). The RV-FAC (47.2% [42.3-52.2] vs. 36.4% [31.1-45], p-value=0.002) showed a significant decrease, and TAPSE (22.5 mm [19.1-24.2] vs. 23 mm [21-25], p-value= 0.55) was comparable. Conclusion Although LV and RV functions did not vary significantly over time in our entire cohort, different patterns of changes were discovered according to baseline function.